Molecular Imaging in Cancer

Bhojani, Mahaveer S.; Laxman, Bharathi; Ross, Brian D.; Rehemtulla, Alnawaz

doi:10.1002/9783527619665.ch27

Cited by 5 publications

(10 citation statements)

References 142 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TRAIL activates extrinsic apoptosis pathways by binding to death receptors 4 and 5 (DR4&DR5) which results in the activation of caspase cascade and apoptosis . To explore the mechanism by which AGPs plus TRAIL enhances the sensitivity of resistant colon cancer cells, we next looked at the expression of DR4 and DR5 using the same cancer and normal cell lines.…”

Section: Resultsmentioning

confidence: 99%

Atmospheric‐Pressure Plasma‐ and TRAIL‐Induced Apoptosis in TRAIL‐Resistant Colorectal Cancer Cells

Ishaq

Han

Kumar

et al. 2015

Plasma Processes & Polymers

View full text Add to dashboard Cite

The ideal anti-cancer treatments are those that can selectively kill cancer cells without harming normal cells. Tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL) is an example of a molecule that can selectively kill cancer cells but not normal cells. However, some tumors are resistant to the TRAIL treatment. We have recently shown that atmospheric cold non-equilibrium gas plasmas (AGPs) selectively induced cell death in melanoma and colorectal cancer cell lines by activating TNF and caspases 3/7 apoptosis pathways. Here, we demonstrated that AGPs can be used to make TRAIL-resistant colorectal cancer cells sensitive to the TRAIL treatment. AGPs plus TRAIL promoted the induction of the death receptor 5 (DR5), thereby enhancing the activation and apoptosis of ROS-dependent caspases 3/7. This study revealed the mechanisms involved in AGP-assisted TRAIL-induced cancer cell death and the associated synergistic effects that AGPs has on TRAILresistant colorectal cancer cells.

show abstract

Section: Resultsmentioning

confidence: 99%

Atmospheric‐Pressure Plasma‐ and TRAIL‐Induced Apoptosis in TRAIL‐Resistant Colorectal Cancer Cells

Ishaq

Han

Kumar

et al. 2015

Plasma Processes & Polymers

View full text Add to dashboard Cite

show abstract

“…16,23 In the recent past, nanotechnology has garnered much attention due to its potential application in cancer, and the National Cancer Institute has constituted an Alliance of Nanotechnology in Cancer 25,24 with focus on the development of novel nanoplatform-based diagnostics, therapeutics and preventive agents. Nanoparticles are colloidal particles (10–100 nm in size) typically synthesized in either aqueous or organic phases.…”

Section: Theranostic Nanoparticles For Imaging and Treatment Of Tumorsmentioning

confidence: 99%

Targeted Imaging and Therapy of Brain Cancer Using Theranostic Nanoparticles

et al. 2010

Self Cite

View full text Add to dashboard Cite

The past decade has seen momentous development in brain cancer research in terms of novel imaging-assisted surgeries, molecularly targeted drug-based treatment regimens or adjuvant therapies and in our understanding of molecular footprints of initiation and progression of malignancy. However, mortality due to brain cancer has essentially remained unchanged in the last three decades. Thus, paradigm-changing diagnostic and therapeutic reagents are urgently needed. Nanotheranostic platforms are powerful tools for imaging and treatment of cancer. Multifunctionality of these nanovehicles offers a number of advantages over conventional agents. These include targeting to a diseased site thereby minimizing systemic toxicity, the ability to solubilize hydrophobic or labile drugs leading to improved pharmacokinetics and their potential to image, treat and predict therapeutic response. In this article, we will discuss the application of newer theranostic nanoparticles in targeted brain cancer imaging and treatment.

show abstract

“…Over the past several years three different noninvasive imaging technologies have been fine tuned for prime time: (A) optical imaging (bioluminescence and fluorescence imaging) [ 22 - 24 ]; (B) magnetic resonance imaging [MRI][ 25 ]; (C) nuclear imaging (e.g single photon emission computed tomography [SPECT] and positron emission tomography [PET]) [ 26 - 28 ]. These have been extensively discussed in a number of reviews and book chapters [ 13 , 14 , 29 - 32 ]. In this article, we will discuss the recent development in the field of bioluminescent optical imaging for monitoring signaling cascades with special emphasis on luciferase complementation platforms for imaging of kinases.…”

Section: Introductionmentioning

confidence: 99%

Novel molecular imaging platform for monitoring oncological kinases

et al. 2010

Self Cite

View full text Add to dashboard Cite

Recent advances in oncology have lead to identification of a plethora of alterations in signaling pathways that are critical to oncogenesis and propagation of malignancy. Among the biomarkers identified, dysregulated kinases and associated changes in signaling cascade received the lion's share of scientific attention and have been under extensive investigations with goal of targeting them for anti-cancer therapy. Discovery of new drugs is immensely facilitated by molecular imaging technology which enables non-invasive, real time, dynamic imaging and quantification of kinase activity. Here, we review recent development of novel kinase reporters based on conformation dependent complementation of firefly luciferase to monitor kinase activity. Such reporter system provides unique insights into the pharmacokinetics and pharmacodynamics of drugs that modulate kinase signaling and have a huge potential in drug discovery, validation, and drug-target interactions.

show abstract

Molecular Imaging in Cancer

Cited by 5 publications

References 142 publications

Atmospheric‐Pressure Plasma‐ and TRAIL‐Induced Apoptosis in TRAIL‐Resistant Colorectal Cancer Cells

Atmospheric‐Pressure Plasma‐ and TRAIL‐Induced Apoptosis in TRAIL‐Resistant Colorectal Cancer Cells

Targeted Imaging and Therapy of Brain Cancer Using Theranostic Nanoparticles

Novel molecular imaging platform for monitoring oncological kinases

Contact Info

Product

Resources

About